louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT01540006: Outpatient Cardiac Rehabilitation in Austria
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Heart Disease
Lead sponsor: Paracelsus Medical University
Sponsor class: OTHER
First posted: 2012-02-28
Enrollment: 1200
Sex: ALL
Minimum age (years): 18
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Any patients with heart disease willing to participate in an ambulant cardiac rehabilitation.

Brief summary: The aim of this prospective trial is the manifestation of guidelines developed for outpatient cardiac rehabilitation in Austria.

The evaluation of prospective and retrospective data is supposed to give evidence on morbidity and/or mortality advantages compared to patients not participating in cardiac rehabilitation programs.

The database created in this context is supposed to pave the way as instrument to document and comprehend quality and cost effectiveness of outpatient cardiac rehabilitation in Austria as a key for quality management.


Eligibility criteria: Inclusion Criteria:

* heart disease

Exclusion Criteria:

* participation in another study within the previous 6 months
* Medical conditions which prevent patients from complying with the exercise program
* Acute infections
* Hypertrophic cardiomyopathy
* Pulmonary artery embolism or phlebothrombosis within the previous 6 months
* Unstable angina pectoris
* Heart failure (NYHA IV)
* Hemodynamically unstable arrhythmia

Primary outcomes:
measure: Physical work capacity (PWC)
timeFrame: 6 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Salzburg
country: Austria
facility: Department of Sports Medicine, Prevention and Rehabilitation Paracelsus Medical University
Study officials:
affiliation: Paracelsus Medical University
name: Prof. Josef Niebauer, MD, PhD, MBA
role: STUDY_CHAIR
References:
citation: Flynn KE, Pina IL, Whellan DJ, Lin L, Blumenthal JA, Ellis SJ, Fine LJ, Howlett JG, Keteyian SJ, Kitzman DW, Kraus WE, Miller NH, Schulman KA, Spertus JA, O'Connor CM, Weinfurt KP; HF-ACTION Investigators. Effects of exercise training on health status in patients with chronic heart failure: HF-ACTION randomized controlled trial. JAMA. 2009 Apr 8;301(14):1451-9. doi: 10.1001/jama.2009.457.
citation: Niebauer J, Hambrecht R, Velich T, Hauer K, Marburger C, Kalberer B, Weiss C, von Hodenberg E, Schlierf G, Schuler G, Zimmermann R, Kubler W. Attenuated progression of coronary artery disease after 6 years of multifactorial risk intervention: role of physical exercise. Circulation. 1997 Oct 21;96(8):2534-41. doi: 10.1161/01.cir.96.8.2534.
citation: O'Connor CM, Whellan DJ, Lee KL, Keteyian SJ, Cooper LS, Ellis SJ, Leifer ES, Kraus WE, Kitzman DW, Blumenthal JA, Rendall DS, Miller NH, Fleg JL, Schulman KA, McKelvie RS, Zannad F, Pina IL; HF-ACTION Investigators. Efficacy and safety of exercise training in patients with chronic heart failure: HF-ACTION randomized controlled trial. JAMA. 2009 Apr 8;301(14):1439-50. doi: 10.1001/jama.2009.454.
Clinical trial NCT06243406: Study on the Biomarkers of Anti-VEGF Treatment for Choroidal Neovascularization
Official title: Study on the Biomarkers to Predict the Response to Anti-vascular Endothelial Growth Factor Treatment for Choroidal Neovascularization
Study type: OBSERVATIONAL
Overall status: NOT_YET_RECRUITING
Conditions: Choroidal Neovascularization
Lead sponsor: Beijing Hospital
Sponsor class: OTHER_GOV
First posted: 2024-02-06
Enrollment: 80
Sex: ALL
Minimum age (years): 18
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Observational model: CASE_ONLY
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients diagnosed with choroidal neovascularization, who received standard 3-monthly anti-VEGF treatment.

Brief summary: Choroidal neovascularization (CNV), also known as subretinal neovascularization, is a proliferative change from choroidal capillaries that has become one of the most important causes of blindness worldwide. CNV can occur in a variety of fundus diseases, including pathologic myopia, polypoidal choroidal vasculopathy. At present, intravitreal injection of anti-vascular endothelial growth factor (VEGF) drugs is the first-line effective treatment for CNV. Although a number of clinical studies have shown that the treatment of CNV with anti-VEGF drugs has achieved good visual and anatomical effects, there are still some patients whose CNV has not decreased significantly or even progressed continuously after treatment. Rapid advances in imaging technology have made it possible to explore the quantitative and qualitative characteristics of choroid and CNV, especially swept source optical coherence tomography angiography (SS-OCTA).

The objectives are to improve the OCTA typing of CNV and analyze the vascular morphological characteristics of each type; to identify the changes in vascular characteristics of CNV after anti-VEGF treatment in vitreous cavity; and to elucidate the predictive effects of neovascularization and choroidal vascular characteristics on visual acuity and anatomic effects of vitreous anti-VEGF drug treatment for CNV.


Eligibility criteria: Inclusion Criteria:

* Age \>18 years old
* Active choroidal neovascularization (activity criteria: blood vessel leakage confirmed by FFA, or subretinal fluid accumulation or bleeding seen by OCT)
* History of anti-VEGF drug therapy
* At least 3 months of follow-up data.

Exclusion Criteria:

* Unable to complete the examination due to severe cataract or vitreous hemorrhage
* Any retinal diseases except choroidal neovascularization, such as multifocal choroiditis, diabetic retinopathy
* History of intraocular surgery

Primary outcomes:
measure: choroidal thickness
timeFrame: 3 months
measure: Central retinal thickness
timeFrame: 3 months
measure: Best-corrected visual acuity
timeFrame: 3 months
Secondary outcomes:
measure: choroidal vascularity index
timeFrame: 3 months
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT02911506: Sleep Quality in Intensive Care Unit Patients at High Risk of Extubation Failure
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Sleep Quality
Extubation Failure
Lead sponsor: Poitiers University Hospital
Sponsor class: OTHER
First posted: 2016-09-22
Enrollment: 72
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Intensive care unit patients, intubated at least 24 hours, at risk of extubation failure

Brief summary: The aim of the study is to evaluate the impact of sleep quality on extubation failure rate in intensive care unit patients at high risk.


Eligibility criteria: Inclusion Criteria:

* Intensive care units patients intubated for at least 24 hours with at least on of the four following risk factor : aged of 65 years or more, any underlying chronic cardiac or lung disease, mechanical ventilation for more than 7 days.
* aged of 18 years or more

Exclusion Criteria:

* peripheral or central nervous system pathology
* known psychiatric pathology or agitation
* patient with decision of no reintubation
* patient refusal
* clinical worsening before polysomnography ( shock with vasopressors drugs, coma, PaO2/FiO2 ratio \< 150 with respiratory distress signs, coma with Glasgow scale \<8)
* pregnant or breastfeeding women
* patient under legal guardianship or protection
* patient with no health insurance coverage
* aged \< 18 years

Primary outcomes:
measure: Evaluation of sleep quality by polysomnography recording on the extubation day.
timeFrame: 24 hours
Secondary outcomes:
Other outcomes:
Locations:
city: Poitiers
country: France
facility: CHU Poitiers
Study officials:
References:
Clinical trial NCT02736006: Decreases in Diffusing Lung Capacity for Carbon Monoxide (DLCO) in Occupational Divers and Their Impact on Decompression Sickness Risks
Official title: Decreases in Diffusing Lung Capacity for Carbon Monoxide (DLCO) in Occupational Divers and Their Impact on Decompression Sickness Risks
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Decompression Sickness
Keywords: Alveolo-capillar membrane
decompression illness
diving
occupational
Lead sponsor: University Hospital, Brest
Sponsor class: OTHER
First posted: 2016-04-13
Enrollment: 16
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: BASIC_SCIENCE

Brief summary: Diving disorders and particularly Decompression sickness (DCS) represent a major concern in recreational and occupational pressure-related activities. As a result of decompression from higher to lower ambient pressure bubbles which are formed in vascular flow and in tissues take part in embolism then resulting in DCS. Individual factors such as vascular or respiratory defects are now considered to increase the risk of this dysbarism disease.

Detailed description: 2 groups of occupational divers will be separated after a fitness medical examination by regarding DLCO decrease or not.

The divers will be evaluated before and 30, 60, 180 minutes after a 20 meters air dive. Venous bubbles will be detected by precordial Doppler 30 minutes after the dive.

In association with this Doppler, Flow Mediated Dilation, blood samples analysing inflammatory and thrombotic factors and other biomarkers will be explored before and after the dive in order to know how vascular and respiratory tracts in this environment react.

Eligibility criteria: Inclusion Criteria:

* Be professional and voluntary diver
* Man or woman aged 18 years or older
* Diffusing Lung Capacity for Carbon Monoxide measured beforehand in the study
* No medical contraindication for hyperbaric
* No hyperbaric constraint in 3 days before the dive
* No prior Decompression sickness
* Not to follow medicinal treatment modifying the vascular endothelial and/or the coagulation and/or the respiratory function
* Patient affiliated to social security
* Informed and signed

Exclusion Criteria:

* Concomitant pathology identified by the Investigator, justifying a contraindication for hyperbaric
* Pregnant and nursing mothers
* Patient who refuse to sign consent form

Primary outcomes:
measure: Venous bubbles will be detected by precordial Doppler
timeFrame: 30 minutes after the dive
Secondary outcomes:
measure: Vascular abnormality
timeFrame: 60 minutes after the dive
measure: Coagulation activation
timeFrame: 60 minutes after the dive
measure: Inflammatory activation
timeFrame: 60 minutes after the dive
Other outcomes:
Locations:
city: Brest
country: France
facility: Brest, University Hospital
Study officials:
References:
Clinical trial NCT06330506: The Effect of Pressure Ulcer Care Package on the Risk of Pressure Ulcer Development
Official title: The Effect of Pressure Ulcer Care Package on the Risk of Surgery-Related Pressure Ulcer Development in Patients Undergoing Orthopaedic Surgery
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Pressure Ulcer
Lead sponsor: Cukurova University
Sponsor class: OTHER
First posted: 2024-03-26
Enrollment: 102
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: SUPPORTIVE_CARE

Brief summary: This study aimed to determine the effect of pressure ulcer care package use on the risk of pressure ulcer development due to surgery in patients undergoing orthopedic surgery. It was planned as a randomized controlled study. The population of the study will consist of patients who underwent surgery in the Orthopaedics and Traumatology Clinic of Doğubayazıt Dr.Yaşar Eryılmaz State Hospital Hospital Hospital of Ağrı Provincial Health Directorate. The sample of the study will consist of patients who volunteered to participate in the study that meets the inclusion criteria. To obtain research data, the Personal Information Form developed by the researcher in line with the literature, 3S Operating Theatre Pressure Wound Risk Assessment Scale, Pressure Wound Regions and Stages Monitoring Form prepared according to NPUAP (2016) Pressure Wound Staging System Form will be used. Statistical analysis of the data obtained from the study will be performed using the SPSS 25 (Statistical Package of Social Science) package program.


Eligibility criteria: Inclusion Criteria:

* Orthopaedics and traumatology department
* Those who have undergone general or spinal anesthesia
* Without any communication problems
* Patients who volunteered to participate in the study

Exclusion Criteria:

* Patients with pre-operative pressure ulcer
* Those who are bedridden
* Patients referred to the intensive care unit after surgery
* Patients who wish to leave the study will be excluded from the study.

Primary outcomes:
measure: Evaluation of pressure ulcer formation
timeFrame: Three days later
Secondary outcomes:
Other outcomes:
Locations:
city: Ağrı
country: Turkey
facility: Dogubayazit Dr Yasar Eryılmaz State Hospital
Study officials:
References:
Clinical trial NCT01018706: Goodness of Clinical History During Stemi PCI
Official title: Goodness of Clinical History During Stemi PCI (GHOST)
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Myocardial Infarction
Keywords: Primary pci
Stent
Medical Hystory
Antiplatelet therapy
Compliance
Lead sponsor: Umberto I Hospital, Frosinone Italy
Sponsor class: OTHER
First posted: 2009-11-25
Enrollment: 400
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Four hundred patients with STEMI treated with primary PCI or rescue PCI.

Brief summary: The purpose of this study is to confirm or confute the hypothesis that in patients treated with primary pci is not always possible to collect an adequate medical history, the investigators created a clinical registry in which the investigators collect current or previous medical history relevant to DES utilization , in two distinct times.

Detailed description: GHOST Registry

Use of drug-eluting stent (DES) in STEMI is sometimes limited, by the concern that adequate information, relating to the current or previous medical history, can not be obtained due to the patient's critical condition. A less than adequate medical history would expose patients treated with DES to a particular risk in case that an absolute or relative contraindication to the required long-term double antiplatelet therapy is not fully elucidated before DES implantation.

To confirm or confute the hypothesis that in patients treated with primary pci is not always possible to collect an adequate medical history, we created a clinical registry in which we collect current or previous medical history relevant to DES utilization , in two distinct times:

Time zero in which the medical history collection is taken in the cath-lab during the primary pci

Time one in which the second medical history collection is taken 4 days after the index procedure when the patient clinical conditions no longer impede an adequate medical history collection.

Eligibility criteria: Inclusion Criteria:

* All consecutive patients presenting with STEMI treated with primary or rescue PCI

Exclusion Criteria:

* Patient in cardiogenic shock and all those patients unable to communicate with the doctors at the moment of medical history taking

Primary outcomes:
measure: Adequacy of medical history collection at the moment of primary pci and 4 days after the index procedure
timeFrame: Adequacy of medical history collection at the moment of primary pci and 4 days after the index procedure
Secondary outcomes:
Other outcomes:
Locations:
city: Frosinone
country: Italy
facility: Interventional cardiology divisione , Umberto I Hospital
Study officials:
References:
Clinical trial NCT00047606: Phase 4 Study Comparing IOP Lowering in OAG or OH in Caucasian or Japanese Subjects C-02-32
Official title: Phase 4 Study to Compare Two Different IOP Lowering Medications for the Treatment of Open Angle Glaucoma or Ocular Hypertension in Caucasian and Japanese Subjects C-02-32.
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE4
Conditions: Open-angle Glaucoma
Ocular Hypertension
Keywords: open-angle
glaucoma
ocular
hypertension
POAG
Iris
Pigmentation
Japanese
Lead sponsor: Alcon Research
Sponsor class: INDUSTRY
First posted: 2002-10-11
Enrollment: 84
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to evaluate safety and efficacy of two different IOP lowering medications after six weeks of treatment in Caucasian and Japanese subjects.


Eligibility criteria: Adults of Caucasian and Japanese Ethnicity

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT02126306: Beta Glucosylceramide for Treatment of NASH
Official title: Beta Glucosylceramide for Treatment of Non Alcoholic Steatohepatitis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
PHASE2
Conditions: Compliance Behavior
Lead sponsor: Hadassah Medical Organization
Sponsor class: OTHER
First posted: 2014-04-30
Enrollment: 23
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Oral administration of betaglucosylceramide was shown effective in reducing inflammation in animal models and was found safe in humans.

Detailed description: Patients with NASH to receive the treatment versus placebo for 40 weeks followed by a liver biopsy.

Eligibility criteria: Inclusion Criteria:

* Biopsy proven NASH

Exclusion Criteria:

* Other therapies

Primary outcomes:
measure: Number of Participants With a Decrease of 2 Points in the Non-Alcoholic Fatty Liver Disease Activity Score (NAS) Analysis is Per Protocol
timeFrame: Total score from baseline compared with week 40.
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Hadassah Medical Organization
name: Yaron Ilan, M.D.
role: STUDY_DIRECTOR
References:
Clinical trial NCT04341506: Non-contact ECG Sensor System for COVID19
Official title: Evaluating Non-contact ECG Sensor System for Early Detection of COVID19
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: COVID-19
Keywords: COVID-19
ECG
Arrhythmia
Lead sponsor: Northwestern Medicine
Sponsor class: OTHER
First posted: 2020-04-10
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: 100 employees of Lake Forrest Memorial Hospital

Brief summary: The purpose of this study is two-fold. First we would like to confirm that non-contact ECG provides equivalency to current contact methods of obtaining ECG data. Second we would like to investigate whether non-contact ECG can detect ECG changes prior to the onset symptoms from COVID19.


Eligibility criteria: Inclusion Criteria:

* Any employee of Lake Forrest Memorial Hospital presenting to work
* Age greater than 18 years-old

Exclusion Criteria:

* Age less than 18 years-old
* Non-employee

Primary outcomes:
measure: ECG changes associated with COVID-19
timeFrame: 3 months
Secondary outcomes:
Other outcomes:
Locations:
city: Chicago
country: United States
facility: Northwestern Medicine
state: Illinois
Study officials:
References:
Clinical trial NCT04020406: Antibacterial Activity of Urea Against Ocular Bacteria
Official title: In Vitro Evaluation of Antibacterial Activity of Urea Solution Against Ocular Bacterial Isolates
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Urea in Blood; High
Lead sponsor: Assiut University
Sponsor class: OTHER
First posted: 2019-07-16
Enrollment: 90
Sex: ALL
Minimum age (years): 5
Maximum age (years): 65
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: individuals with any ocular infection

Brief summary: Antibacterial properties of urea was tested against 35 isolates from ocular infections.

Detailed description: In vitro susceptibility testing was performed with commercially available antibiotic discs, homemade urea discs saturated with urea solution at a concentration of 96 mmol. The weight of urea in one drop = 0.37 mg, in one ml = 10.34 mg (5 microliter/ disc) discs and combined discs (antibiotic discs to which urea solution was added). Combined discs provided better in vitro susceptibility results than antibiotics alone.

Scanning electron micrographs of bacterial isolates incubated overnight with urea solution showed marked disruption of bacterial aggregative patterns and irregularities of their cell walls.

Western blotting showed marked reduction in total proteins in bacterial isolates incubated overnight with urea solution. These findings may explain the possible mechanisms for antibacterial activity of urea solution as a result of protein denaturation.

Eligibility criteria: Inclusion Criteria:

* ocular infection

Exclusion Criteria:

* Local antibiotics treatment

Primary outcomes:
measure: Antibacterial effect of Urea Solution against Ocular Bacterial
timeFrame: 6 month
Secondary outcomes:
Other outcomes:
Locations:
city: Assiut
country: Egypt
facility: Hassan Lotfy Fahmy
Study officials:
affiliation: Assiut T
name: Hassan 58 Lotfy, Professor
role: PRINCIPAL_INVESTIGATOR
References: